Aspirin irreversibly inhibits the enzyme cyclooxygenase-1 and depresses the production of thromboxane A 2 , and also exerts antiplatelet eŠects. On the other hand, it also depresses the production of prostaglandin E 2 (PGE 2 ) and induces gastroduodenal lesions, which are often seen in patients taking aspirin. The aim of this study was to clarify the degree of gastroduodenal lesions induced by low-dose aspirin. We investigated the incidence rate of such lesions induced by aspirin and non-steroidal anti-in‰ammatory drugs (NSAIDs), and performed theoretical evaluations in a retrospective study. The incidence rates of gastroduodenal lesions in the low-dose aspirin (n＝1103) and NSAIDs (n＝1856) groups were 2.54％ and 0.27％, respectively, which was signiˆcantly greater in the aspirin group. Furthermore, the calculated value of inhibition rate of gastric PGE 2 was signiˆcantly correlated with the actual value after administration of aspirin or NSAIDs (r＝0.902, p＜0.05), which suggested that the calculated value re‰ected the actual value. The calculated value of aspirin (98.9％) was higher than that of NSAIDs (3.67 70.8％) after administration of the drugs with the standard doses. Ourˆndings indicate that the incidence rate of gastroduodenal lesions induced by low-dose aspirin was higher than that of those induced by NSAIDs. Therefore, we were able to perform a theoretical evaluation of the occurrence of gastroduodenal lesions.
に文献より得られた胃生検片中の Treatment condition; aspirin, 2 h after administration 81 mg once daily for 46 days; naproxen, 4 h or more after administration 500 mg twice daily for 28 days; ibuprofen, 90 min after administration 400 mg 3 times daily for 10 days; Indometacin-1, 4 5 h after administration 50 mg 3 times daily for 28 days; Indometacin-2, 8 10 h after administration 50 mg 3 times daily for 10 days; Piroxicam, 0 4 h after administration 20 mg once daily for 7 days. 
